Document Detail

Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C.
MedLine Citation:
PMID:  19957327     Owner:  NLM     Status:  MEDLINE    
Interferon treatment for chronic hepatitis C reduces the incidence of hepatocellular carcinoma (HCC) in sustained responders. However, estimation of the effect of interferon treatment on HCC development in nonresponders is yet to be fully implemented. We conducted a meta-analysis of 3 randomized controlled trials and 6 prospective cohort studies, including 3,246 patients (1,922 patients received interferon treatment) to estimate the effect of single-course interferon treatment on HCC development in patients with chronic hepatitis C. Single-course interferon treatment prevented HCC development (RR 0.45; 95% CI 0.31-0.65). This preventive effect was shown even in nonresponders (RR 0.48; 95% CI 0.25-0.90). By subgroup analyses, single-course interferon treatment reduced HCC incidence in cirrhotic patients (RR 0.49; 95% CI 0.29-0.84), patients with annual HCC incidence less than 3% in control group (RR 0.42; 95% CI 0.26-0.66) and patients with annual HCC incidence of 3% or more in control group (RR 0.46; 95% CI 0.26-0.83). Furthermore, HCC incidence was reduced in 3 studies with follow-up period less than 5 years (RR 0.38; 95% CI 0.21-0.66) and in 6 studies with follow-up period of 5 years or more (RR 0.46; 95% CI 0.28-0.76). In conclusion, single-course interferon treatment was shown to prevent HCC development in chronic hepatitis C, even in nonresponders. This preventive effect may be speculated to be due to anti-inflammatory effect on persistent necro-inflammation and blocking progression of fibrosis in liver. Even if sustained virological response is not achieved, interferon may be worth administering in order to reduce HCC incidence in patients with chronic hepatitis C.
Yasuhiro Miyake; Yoshiaki Iwasaki; Kazuhide Yamamoto
Related Documents :
8314497 - A controlled trial of high dose interferon, alone and after prednisone withdrawal, in t...
1730277 - Remission may continue after termination of rifn alpha-2b treatment for essential throm...
12084557 - Transient biochemical response in interferon therapy decreases the development of hepat...
14583847 - Predictors of long-term immunological outcome in rebounding patients on protease inhibi...
25434837 - Assessment of voiding after sling: a randomized trial of 2 methods of postoperative cat...
19422707 - Predictors of packed red cell transfusion after isolated primary coronary artery bypass...
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  127     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-06-28     Completed Date:  2010-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  989-96     Citation Subset:  IM    
Department of Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Carcinoma, Hepatocellular / prevention & control*,  virology
Hepacivirus / physiology*
Hepatitis C, Chronic / drug therapy*
Interferons / therapeutic use*
Liver Neoplasms / prevention & control*,  virology
Prospective Studies
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Antiviral Agents; 9008-11-1/Interferons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection:...
Next Document:  Ezetimibe reverses the inhibitory effects of dietary cholesterol on mammary tumorigenesis in rats.